Trials / Terminated
TerminatedNCT02605044
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
A Prospective, Multicenter, Randomized, Double Blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI (Irinotecan, 5-fluorouracil and Folinic Acid) to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- AB Science · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Masitinib (AB1010) | |
| DRUG | FOLFIRI |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2015-11-16
- Last updated
- 2019-02-11
Locations
3 sites across 3 countries: France, Singapore, United Kingdom
Source: ClinicalTrials.gov record NCT02605044. Inclusion in this directory is not an endorsement.